Cargando…

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setting remain poorly defined. METHODS: We retrospectively review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuanquan, Psutka, Sarah P., Parikh, Anish B., Li, Mingjia, Collier, Katharine, Miah, Abdul, Mori, Sherry V., Hinkley, Megan, Tykodi, Scott S., Hall, Evan, Thompson, John A., Yin, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385597/ https://www.ncbi.nlm.nih.gov/pubmed/35304832 http://dx.doi.org/10.1002/cam4.4679

Ejemplares similares

Salvage nivolumab and ipilimumab after prior anti‐PD‐1/PD‐L1 therapy in metastatic renal cell carcinoma: A meta‐analysis
por: Yang, Yuanquan, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
por: Goff, Peter H., et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition
por: Daly, Roger J., et al.
Publicado: (2022)

Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection
por: Bi, Jianping, et al.
Publicado: (2021)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition
por: Börner, J. H., et al.
Publicado: (2023)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression
por: Xu, Xianglai, et al.
Publicado: (2023)

Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients
por: Xu, Xianglai, et al.
Publicado: (2023)

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report
por: Johnson, Kai, et al.
Publicado: (2021)

TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer
por: Looney, Timothy John, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Up-regulates Interleukin-6 in Cancer Cells and Induces Subsequent Development of Interstitial Pneumonia
por: Ishiguro, Yukari, et al.
Publicado: (2013)

Neurosarcoidosis following Immune Checkpoint Inhibition
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Resistance to Checkpoint Inhibition in Cancer Immunotherapy
por: Barrueto, Luisa, et al.
Publicado: (2020)

Pneumocystis Pneumonia: Checkpoint Inhibition to the Rescue?
por: Better, Julian, et al.
Publicado: (2020)

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
por: Newton, Jared M., et al.
Publicado: (2019)

Monalizumab: inhibiting the novel immune checkpoint NKG2A
por: van Hall, Thorbald, et al.
Publicado: (2019)

A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
por: Lal, Jessica Castrillon, et al.
Publicado: (2021)

Manzamenones Inhibit T-Cell Protein Tyrosine Phosphatase
por: Wakuda, Yusuke, et al.
Publicado: (2006)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
por: Montagna, Daniela R., et al.
Publicado: (2022)

Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study
por: Sillah, Arthur, et al.
Publicado: (2022)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
por: Clennon, Anna, et al.
Publicado: (2023)

Homeostasis of the ER redox state subsequent to proteasome inhibition
por: Oku, Yuki, et al.
Publicado: (2021)

Cryptotanshinone inhibits IgE-mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mast cells
por: Buyanravjikh, Sumiyasuren, et al.
Publicado: (2021)

THE EFFECTS OF HALOTHANE ON CULTURED MOUSE NEUROBLASTOMA CELLS : I. Inhibition of Morphological Differentiation
por: Hinkley, Robert E., et al.
Publicado: (1974)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Cardiac Complications in Immune Checkpoint Inhibition Therapy
por: Tajiri, Kazuko, et al.
Publicado: (2019)

Cancer immunotherapy: Moving beyond checkpoint inhibition
por: Boes, Marianne
Publicado: (2018)

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
por: Bidnur, S., et al.
Publicado: (2016)

Impact of age on the toxicity of immune checkpoint inhibition
por: Samani, Amit, et al.
Publicado: (2020)

Management of hepatitis B in the era of checkpoint inhibition
por: Dutcher, Janice
Publicado: (2020)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pjg6fvbtk4r27ukn5s41vli586